Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: January 2007

VistaGen’s (VSTA) AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications

VistaGen Therapeutics, Inc., an emerging biopharmaceutical company, focused on stem cell technologies, to discover, develop and commercialize novel small molecule drugs and protein therapeutics for neurological disorders and diabetes, announced positive results from preclinical studies of AV-101, its lead drug … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment